prior to the addition of drugs. To produce chronic toxicity, long-term inhibition of glutamate uptake was effected by incubating slices with culture medium containing various concentrations of THA or PDC (5, 6). At very high concentrations (>1 mM), THA can have weak actions at the N-methyl-D-aspartate (NMDA) receptor, a property not shared by PDC (5). Transport inhibitors were maintained in cultures by replenishing them at each change in culture medium. In all experiments, potentially neuroprotective drugs were added repeatedly, either in the presence or absence of a glutamate transport inhibitor, again beginning after 8 days in culture. Motor-neuron toxicity was monitored by two methods: (i) biochemical analysis of tissue choline acetyltransferase activity (ChAT) and (ii) microscopic morphology. ChAT activity is largely restricted to ventral motor neurons in rat lumbar spinal cord, and assays of ChAT activity have been used as a reliable marker for motor neurons (7-9). Motor neurons were also visualized in organotypic cultures by histological analysis of stained semithin plastic sections and by immunohistochemistry.
toxicity and appears to be mediated by the action of non-Nmethyl-D-aspartate receptors. This data supports the hypothesis that the slow loss of motor neurons in amyotrophic lateral sclerosis could be due, in part, to defective glutamate transport.
Amyotrophic lateral sclerosis (ALS) is characterized clinically by progressive weakness and wasting of muscles caused by a slow loss of large and small neurons, predominantly motor neurons, in the ventral spinal cord, brainstem, and motor cortex. Previous studies (1, 2) , including those showing increased cerebrospinal fluid glutamate concentrations, have demonstrated that the disease is associated with abnormal glutamate metabolism. Recently, a loss of high-affinity glutamate transport was identified in certain brain regions and spinal cord of patients with ALS (3). These results suggested that the defect in glutamate transport could be responsible for sustained elevations in extracellular glutamate, which might be injurious to neurons. Under normal conditions, glutamate is rapidly cleared from the synaptic cleft by high-affinity high-capacity transport into both presynaptic terminals and nearby astrocytes (4) . The glutamate carrier can be specifically and potently inhibited by both threohydroxyaspartate (THA) and pyrrolidine dicarboxylic acid (PDC) (5, 6) . We developed an in vitro model of defective glutamate transport, by chronically blocking the glutamate carrier, to test the hypothesis that inefficient glutamate transport would result in elevation of extracellular glutamate, and if sustained, might produce slowly developing neurotoxicity. We used organotypic spinal cord cultures in this model, cultures that have the advantage of long-term survival with partially preserved synaptic connections, to mimic as closely as possible the transport defect that is known to occur in ALS (3) .
MATERIALS AND METHODS
Experimental Design. In all experiments, cultures were allowed an 8-day recovery period after initial preparation,
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prior to the addition of drugs. To produce chronic toxicity, long-term inhibition of glutamate uptake was effected by incubating slices with culture medium containing various concentrations of THA or PDC (5, 6) . At very high concentrations (>1 mM), THA can have weak actions at the N-methyl-D-aspartate (NMDA) receptor, a property not shared by PDC (5) . Transport inhibitors were maintained in cultures by replenishing them at each change in culture medium. In all experiments, potentially neuroprotective drugs were added repeatedly, either in the presence or absence of a glutamate transport inhibitor, again beginning after 8 days in culture. Motor-neuron toxicity was monitored by two methods: (i) biochemical analysis of tissue choline acetyltransferase activity (ChAT) and (ii) microscopic morphology. ChAT activity is largely restricted to ventral motor neurons in rat lumbar spinal cord, and assays of ChAT activity have been used as a reliable marker for motor neurons (7) (8) (9) . Motor neurons were also visualized in organotypic cultures by histological analysis of stained semithin plastic sections and by immunohistochemistry.
Organotypic Spinal Cord Cultures. Organotypic spinal cord cultures were prepared using lumbar spinal cord slices from 8-day-old rat pups. Neonatal rat pups were decapitated, and the spinal cords were rapidly harvested and cultured by a modification of described methods (10, 11 (14) . 
RESULTS
Spinal cord cultures were reliably maintained for as long as 3 months and had well-preserved organotypic morphology. Dorsal horn neurons could be identified by the typical high density of tightly packed small cells (Fig. 1A) . Somatic motor neurons were readily identifiable by their large size and distinctive grouping in the ventral lateral region ofthe explant culture (Fig. 1A) . Immunohistochemical stains for the motorneuron-specific enzyme ChAT identified clumps of motor neurons in the lateral ventral horn region (Fig. 1B) .
ChAT activity initially dropped precipitously for the first several days after culturing but gradually returned to baseline values (Fig. 2) , levels that were also comparable to agematched uncultured lumbar spinal cord tissue (data not shown). The initial drop in enzyme activity is a typical response of motor neurons to axotomy, not a loss ofcells; the return of ChAT activity reflects the recovery from this initial injury (7) (8) (9) . This conclusion was supported by morphological analysis of the ventral motor neurons that were normal in appearance after a period of mild reversible chromatolytic changes limited to the first 3 weeks in culture (Fig. 3A) . Furthermore, counts of ChAT-positive neurons revealed a stable population of ventral motor neurons throughout the period of the culture (Fig. 4A) .
Chronic inhibition of glutamate transport with THA produced a dose-dependent persistent elevation of glutamate levels in the culture medium (Fig. 5) . Inhibition of glutamate transport by THA also produced a slow loss of the motor neuron marker ChAT, and the rate at which toxicity occurred was dose-dependent ( Fig. 2) . High concentrations of THA (500 ,uM), produced motor-neuron toxicity after 1 week; at lower concentrations of THA (100 AM), toxicity began after 2-3 weeks. Lower concentrations of THA (25 ,uM) caused only slight decreases in ChAT after 45 days, and 10 AM THA was not toxic up to 72 days in culture. Similar results were found using comparable concentrations of PDC (Table 1) .
To test whether delayed toxicity was dependent on the developmental stage of the tissue, organotypic cultures were also maintained for 30 and 50 days before the addition of transport inhibitors. We still observed delayed toxicity with (Fig. 3B ), which were not seen in age-matched control cultures. After 14 days of treatment with high concentrations ofTHA, there was severe vacuolar degeneration of motor neurons (Fig. 3C) 33.5 ± 8.5* 0** After 8 days in culture, PDC was added to the culture medium to 100 or 400 ,uM and was maintained in all subsequent biweekly changes of medium. Data are expressed as percent of control ChAT activity (mean ± SEM). Each mean represents four to eight replicate culture wells, each containing five slices. Statistical significance (independent t test) of PDC treatment vs. control: *, P < 0.05; **, P <0.01. a 70% reduction of ChAT (P < 0.01), somatostatin levels were not significantly changed from control levels.
To determine whether chronic toxicity was mediated by a specific glutamate receptor subtype, cultures were incubated concomitantly with the transport inhibitor and various glutamate receptor antagonists, including: the noncompetitive NMDA receptor antagonist MK-801, the competitive NMDA antagonist CPP, the noncompetitive non-NMDA receptor antagonist GYKI-52466, or the competitive non-NMDA antagonist CNQX (17, 18) . Both GYKI-52466 and CNQX provided nearly complete protection of motor neurons from glutamate-mediated toxicity at 22, 25, and 29 days in culture. MK-801 and CPP were unable to protect motor neurons from toxicity mediated by long-term inhibition ofglutamate uptake (Fig. 6A) .
When the potent agonists NMDA or AMPA (a selective non-NMDA agonist) were directly and repeatedly added to A Antagonists culture medium over a range of concentrations, only AMPA was capable of producing motor-neuron toxicity (Fig. 6B) .
Ifthe increased extracellular glutamate, due to inhibition of glutamate transport by THA, was the cause of slowly progressive neurotoxicity, then interruption of the cellular release of glutamate should protect against this toxicity. MSO irreversibly inhibits glutamine synthetase, a synthetic enzyme for neurotransmitter glutamate (4), thereby depleting presynaptic pools of neurotransmitter glutamate (19, 20) . When spinal cord cultures were incubated with 1 mM MSO, the culture medium glutamate levels were not elevated and the motor neurons were no longer susceptible to the toxic effects of high concentrations of THA (Fig. 6A) .
TTX can block activity-dependent release of neurotransmitter and can be neuroprotective (21) . When TTX (1 or 10 ,uM) was continuously added to cultures, medium glutamate levels were not increased and motor neurons were no longer susceptible to the toxic effects of THA (Fig. 6A) .
DISCUSSION
Organotypic cultures prepared from postnatal rat lumbar spinal cord provide a unique method to chronically study motor-neuron properties. We found that the cultures could be maintained with appropriate morphological features, including a stable population of ventral motor neurons, for at least 3 months. By exposing cultures to specific glutamate transport inhibitors, we have developed a reproducible model that mimics a feature of sporadic ALS, that is, the loss of glutamate transport. Using this paradigm, we have discovered two significant characteristics of glutamate toxicity in spinal cord neurons (i.e., over weeks to months) and (ii) motor neurons are uniquely sensitive to non-NMDA but not NMDA receptor-mediated toxicity. THA or PDC produced motor-neuron toxicity in a dosedependent fashion by blocking glutamate uptake, which leads to a chronic accumulation of extracellular glutamate. Transport blockade, the mechanism by which THA produced toxicity, was indirectly verified in the experiments employing drugs (MSO and TTX) that could interfere with presynaptic release of glutamate. The neuroprotection afforded by both these agents verifies the need for glutamate synthesis and release in THA-mediated neurotoxicity.
Motor-neuron loss in this model was confirmed by three methods: biochemical measurements of ChAT, counts of large ventral horn cells in serial plastic sections of organotypic cultures, and counts of ChAT-immunoreactive large ventral horn cells. The loss of ChAT activity in homogenates corresponded closely with both the loss of large ventral horn neurons and the loss of ChAT-positive cells. Thus, in this paradigm, chronic toxicity represents true loss of motor neurons rather than just down regulation of ChAT activity.
Morphologic evaluation ofthe cultures revealed that motor neurons were preferentially altered first in this model, as shown by the vacuolar changes seen even before the biochemical indices had changed. The disparate effect of THA on ChAT and somatostatin also suggests an initial selective vulnerability to THA-induced glutamate toxicity among motor neurons rather than dorsal horn cells.
Glutamate toxicity can be mediated by both NMDA and non-NMDA glutamate receptor subtypes in acute models of cell death (22) . Motor neurons appear to possess both NMDA and non-NMDA receptors (23) (24) (25) ; however, the relative preponderance of these subtypes on motor neurons is not known. The postnatal motor neurons used in this culture were particularly susceptible to glutamate toxicity mediated through the non-NMDA receptors, as shown by the fact that non-NMDA antagonists could effectively prevent the uptakemediated chronic neurotoxicity and that AMPA was a potent motor-neuron toxin. However, NMDA antagonists were not neuroprotective, and NMDA itself was not toxic to motor neurons. Acute non-NMDA-mediated toxicity affecting motor neurons has been suggested by studies of chicken spinal cord in vitro (26) and neonatal rats in vivo (27) . In contrast, our model clearly demonstrates selective non-NMDAmediated slow neurotoxicity.
The cellular mechanisms by which cells slowly degenerate after chronic inhibition of glutamate uptake are not known, although it appears to be mediated via non-NMDA receptors.
Could the cellular localization of non-NMDA receptors or the pattern of non-NMDA receptor subunit combinations determine the selective loss ofmotor neurons in ALS? Interestingly, genetic analysis ofthe autosomal dominant form ofALS, which is quite similar phenotypically to the more prevalent sporadic ALS, has revealed a mutation of the Cu/Zn superoxide dismutase gene (28) . Superoxide dismutase converts superoxide anions into H202 and 02. Excess oxygen radicals have been postulated to participate in the injury associated with glutamate acting at non-NMDA receptors (29) . Perhaps a selective localization of glutamate receptor subtypes and abnormal cellular mechanisms for detoxification of free radicals are responsible for the slow death ofmotor neurons in our culture and in familial ALS (30) . Abnormalities in other cellular cascades (e.g., calcium homeostasis, inositol phospholipid metabolism, and agerelated mitochondrial gene defects) could also act in series with ongoing glutamate-mediated toxicity to produce the selective chronic motor-neuron degeneration recognized as the phenotype of ALS. The organotypic spinal cord culture model provides a convenient way to test some of these hypotheses.
Based on this model of chronic neurotoxicity, the selective slow loss of motor neurons observed in ALS could be due, in part, to the loss of glial or neuronal glutamate transport, with concomitant persistent exposure of neurons to elevated synaptic glutamate. The protection from chronic motor-neuron toxicity provided by non-NMDA antagonists or inhibitors of presynaptic release may have important therapeutic implications.
